Winning entry in art competition depictsbeauty, wholeness despite mastectomy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Architect Nikko Shabtai, of Beverly Hills, Calif., took fi rst prize in the Oncology on Canvas event, sponsored by Eli Lilly in partnership with the National Coalition for Cancer Survivorship.

Architect Nikko Shabtai, of Beverly Hills, Calif., took first prize in the Oncology on Canvas event, sponsored by Eli Lilly in partnership with the National Coalition for Cancer Survivorship.

Mr. Shabtai used a painter’s knife, rather than a paintbrush, to create “As I Am, Beautiful and Whole,” which won the Best of Exhibition trophy and an award of $10,000 donated to the Cancer Schmancer Foundation on his behalf.

Mr. Shabtai’s acrylic painting portrays a woman who appears to have undergone a mastectomy. “I was painting the model in my painting workshop when I picked up my knife instead of a brush and painted her without a breast,” Mr. Shabtai explained in a written statement. He said he realized that his inspiration for this piece was the breast cancer diagnosis, and subsequent mastectomy, that a family member had recently experienced.

 

In all, 19 winners were selected in the Oncology on Canvas: Expressions of a Cancer Journey Art Competition and Exhibition, with 26 prizes given to 22 cancer charities.

Elizabeth Menges of Boston took home second prize for a series of six small oil paintings that detail the morning dressing routine of a breast cancer survivor.

New York-based breast cancer survivor Barbara E. Litke and artist Nash Hyon, of Wilton, Conn., tied for third place.

 

 

 

 

 

 

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content